Medicine Recommendations

Treating migraine (NICE TA919)

NICE TA919 - Rimegepant for treating migraine

Risankizumab for treating moderate to severe plaque psoriasis (NICE TA596)

NICE TA 596 - Risankizumab for treating moderate to severe plaque psoriasis

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA803

NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Previously treated moderately to severely active Crohn's disease (NICE TA888)

NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis 

Acute and chronic psychoses, mania; short-term treatment of persistent aggression in patients with moderate to severe Alzheimer's dementia unreponsive to non-pharmacological interventions and where there is a risk of harm to self or others; short-term treatment of persistent aggression in conduct disorder

MHRA Drug Safety Update - Drug name confusion

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

MHRA Drug Safety Update - Drug name confusion

MHRA Drug Safety Update - Risperidone and paliperidone: risk of floppy iris syndrome

Rheumatoid arthritis (LSCMMG pathway)

Autoimmune haemolytic anaemia

Idiopathic thrombocytopenia purpura

Membranous glomerulonephritis

Relapsing steroid sensitive nephrotic syndrome in adults

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and extended prevention of recurrent DVT and PE in adults

NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Prevention of venous thromboembolism after total hip or total knee replacement in adults (NICE TA170)

NICE TA170 - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults 

Prevention of stroke and systemic embolism in people with atrial fibrillation (NICE TA256)

NICE TA256 - Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Treatment of deep vein thrombosis and prevention of recurrent DVT and pulmonary embolism (NICE TA261)

NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Pulmonary embolism and recurrent venous thromboembolism
(NICE TA287)

NICE TA287 - Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

Preventing adverse outcomes after acute management of acute coronary syndrome (NICE TA335)

NICE TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Prevention of cardiac events in patients with coronary (CAD) or peripheral artery Disease (PAD) (NICE TA607)

NICE TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

Alzheimer's Dementia (NICE TA 217)

NICE TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease